Experimental cell therapy aims to fight tough lymphomas
NCT ID NCT07093073
Summary
This early-phase study is testing a new version of CAR-T cell therapy called U01 (ssCART-19) in adults and children (ages 2-75) with B-cell lymphoma that has returned or not responded to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to better target lymphoma cells, and infuse them back. The main goals are to see if the treatment is safe and if it can shrink or eliminate tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hebei Yanda Lu Daopei Hospital
RECRUITINGHebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin First Central Hospital
RECRUITINGTianjin, 300190, China
Contact Email: •••••@•••••
-
Tongji Hospital of Tongji University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.